CRVO will explode next week

Earnings Results: CerVoMed surpassed analysts' expectations in terms of earnings this year and last year. After the first quarter announcement, the stock soared from $16 to $25. Analysts predict that the second quarter will also be better than the previous quarter, so there is a possibility that it will once again exceed analysts' expectations.

Recent stock price trends: On 8/6, the stock price rose from $13 to $16 early in the morning, and the trading volume also increased from 0.05 million to 0.36 million. However, after that, many investors sold in about an hour after the market opened, and the stock price plummeted. This is because Yahoo Finance mistakenly set the earnings report date for that day, so day traders and individual investors mistakenly believed that day was the earnings announcement date. The actual earnings announcement date is 8/13, and if things go as expected, there is a high possibility that the stock price will rise to 0.35 million again.

Pricing Targets and Drug Development: CervoMed's average price target is $52, but Morgan Stanley set a target of $35 a few weeks ago. This is because trials for new drug development are underway, and results are expected to be announced in December of this year. This high price target and expectations for test results are increasing stock attention.

We don't know if the test results are good, but Morgan Stanley believes that is likely. From my point of view, the stock is highly volatile, so I expect it could reach $20 on Tuesday morning. We recommend checking out Morgan Stanley's report on CervoMed and its earnings report for the first quarter.